Antitumor regimens with gemcitabine are safe for tumor patients with COVID-19. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full text ...
– NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at ...
SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and collaborators at The University of Texas MD Anderson Cancer Center today presented late-breaking results from a Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback